222 related articles for article (PubMed ID: 37484531)
1. Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer.
Xie X; Liang H; Jiangting W; Wang Y; Ma X; Tan Z; Cheng L; Luo Z; Wang T
Front Mol Biosci; 2023; 10():1198557. PubMed ID: 37484531
[No Abstract] [Full Text] [Related]
2. CEP55: Implications for Immunotherapy and Survival in Hepatocellular Carcinoma.
Wang Y; Zhang L; Tian J; Luo B; Yao J; Yang Y
Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38847172
[TBL] [Abstract][Full Text] [Related]
3. α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.
Tang Y; Thiess L; Weiler SME; Tóth M; Rose F; Merker S; Ruppert T; Schirmacher P; Breuhahn K
Cell Commun Signal; 2023 Jun; 21(1):162. PubMed ID: 37381005
[TBL] [Abstract][Full Text] [Related]
4. CEP55: an immune-related predictive and prognostic molecular biomarker for multiple cancers.
Li GS; Zhang W; Huang WY; He RQ; Huang ZG; Gan XY; Yang Z; Dang YW; Kong JL; Zhou HF; Chen G
BMC Pulm Med; 2023 May; 23(1):166. PubMed ID: 37173675
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
6. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target.
Zaki MSA; Eldeen MA; Abdulsahib WK; Shati AA; Alqahtani YA; Al-Qahtani SM; Otifi HM; Asiri A; Hassan HM; Emam Mohammed Ahmed H; Dawood SA; Negm A; Eid RA
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175004
[TBL] [Abstract][Full Text] [Related]
8. CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification.
Wang G; Chen B; Su Y; Qu N; Zhou D; Zhou W
Cells; 2023 Oct; 12(20):. PubMed ID: 37887301
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer.
Yang L; He Y; Zhang Z; Wang W
Biomed Res Int; 2020; 2020():4139320. PubMed ID: 32337246
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
Zhou L; Liu S; Li X; Yin M; Li S; Long H
Mol Med Rep; 2019 May; 19(5):3485-3496. PubMed ID: 30896867
[TBL] [Abstract][Full Text] [Related]
12. Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer.
Wangmo D; Gates TJ; Zhao X; Sun R; Subramanian S
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250876
[TBL] [Abstract][Full Text] [Related]
13. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
14. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
15. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
[TBL] [Abstract][Full Text] [Related]
16. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
17. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
18. Prognostic hub gene CBX2 drives a cancer stem cell-like phenotype in HCC revealed by multi-omics and multi-cohorts.
Meng Q; Zhou Q; Chen X; Chen J
Aging (Albany NY); 2023 Nov; 15(22):12817-12851. PubMed ID: 37980163
[TBL] [Abstract][Full Text] [Related]
19. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
